{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:59:57Z","timestamp":1761292797240,"version":"3.28.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[1990,12,1]],"date-time":"1990-12-01T00:00:00Z","timestamp":660009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1990,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The racemic compound indobufen and its (+)-and (\u2014)-enantiomers have been compared for their effects on blood platelet function and rat carrageenan pleurisy. The antiplatelet properties were studied in-vitro in human platelets by measuring the inhibition of platelet aggregation and generation of serum thromboxane (Tx) B2. In-vivo, the antiplatelet and anti-inflammatory properties were studied in rats by measuring the inhibition of serum TxB2, the amount of 6-keto-PGF1\u03b1 in pleural exudate and pleural exudate volume. In all tests the (+)-enantiomer was slightly more potent than the racemate, while the (\u2014)-enantiomer was far less potent. In the same rats, treatment with the lowest doses of the compounds giving 90% inhibition of serum thromboxane B2 generation was associated with occasional macroscopic lesions of the gastric mucosa.<\/jats:p>","DOI":"10.1111\/j.2042-7158.1990.tb07049.x","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T13:39:29Z","timestamp":1302701969000},"page":"885-887","source":"Crossref","is-referenced-by-count":16,"title":["The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (\u00b1)-indobufen"],"prefix":"10.1093","volume":"42","author":[{"given":"Chiara","family":"Cerletti","sequence":"first","affiliation":[{"name":"Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Giulio Bizzozero Laboratory of Platelet and Leucocyte Pharmacology , Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Manarini","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Giulio Bizzozero Laboratory of Platelet and Leucocyte Pharmacology , Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Colombo","sequence":"additional","affiliation":[{"name":"Opioid Neuropharmacology Unit , via Eritrea 62, 20157 Milano,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tavani","sequence":"additional","affiliation":[{"name":"Opioid Neuropharmacology Unit , via Eritrea 62, 20157 Milano,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1990,12,1]]},"reference":[{"key":"2024103110431908400_cit1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6989(79)80090-9","article-title":"Indobufen, a new inhibitor of platelet aggregation. Studies on guinea pigs","volume":"11","author":"Bergamaschi","year":"1979","journal-title":"Pharmacol. Res. Comm."},{"key":"2024103110431908400_cit2","first-page":"293","article-title":"In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production","volume":"17","author":"Cattaneo","year":"1987","journal-title":"Haemostasis"},{"key":"2024103110431908400_cit3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1172\/JCI112569","article-title":"Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclo-oxygenase activity in platelets and presystemic but not systemic vessels","volume":"78","author":"Cerletti","year":"1986","journal-title":"J. Clin. Invest."},{"key":"2024103110431908400_cit4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0014-2999(89)90156-8","article-title":"Antiinflammatory action of salicylates: aspirin is not a prodrug for salicylate against rat carrageenin pleurisy","volume":"159","author":"Chiabrando","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"2024103110431908400_cit5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2141.1979.tb03797.x","article-title":"Prostaglandins as inhibitors of human platelet aggregation","volume":"43","author":"Di Minno","year":"1979","journal-title":"Br. J. Haematol."},{"key":"2024103110431908400_cit6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF00558435","article-title":"Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K3920), an inhibitor of platelet aggregation, after a single dose in man","volume":"15","author":"Fuccella","year":"1979","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2024103110431908400_cit7","first-page":"243","article-title":"Ex vivo and in vitro study of the effects of indobufen on endogenous and exogenous arachidonic acid metabolism by platelets","volume":"42","author":"Pinto","year":"1987","journal-title":"Curr. Ther. Res."},{"key":"2024103110431908400_cit8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/009127008002000502","article-title":"Clinical pharmacology studies with indobufen (K3920), inhibitor of platelet aggregation","volume":"20","author":"Vinazzer","year":"1980","journal-title":"J. Clin. Pharmacol."},{"key":"2024103110431908400_cit9","first-page":"2588","article-title":"Pathway of onset, development, and decay of carrageenan pleurisy in the rat","volume":"41","author":"Vinegar","year":"1982","journal-title":"Fed. Proc."},{"key":"2024103110431908400_cit10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/284271a0","article-title":"Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa","volume":"284","author":"Whittle","year":"1980","journal-title":"Nature"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.1990.tb07049.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/42\/12\/885\/60268959\/j.2042-7158.1990.tb07049.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/42\/12\/885\/60268959\/j.2042-7158.1990.tb07049.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T11:16:29Z","timestamp":1730373389000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/42\/12\/885\/6164536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,12,1]]},"references-count":10,"journal-issue":{"issue":"12","published-online":{"date-parts":[[1990,12,1]]},"published-print":{"date-parts":[[1990,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.1990.tb07049.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[1990,12]]},"published":{"date-parts":[[1990,12,1]]}}}